Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

BIOSTRAT BIOTECH CONSULTING ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.2% 1.2%   Bankruptcy risk   1.2% 1.2% 1.7% 2.3% 0.8% 1.3% 7.3% 7.3%   Credit score (0-100)   84 84 73 63 91 78 33 33   Credit rating   A A A BBB AA A BBB BBB   Credit limit (kDKK)   140.4 155.9 125.9 1.4 5,940.0 687.3 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,155 467 571 98.7 -274 -180 0.0 0.0   EBITDA   385 217 171 98.7 -774 -1,030 0.0 0.0   EBIT   385 217 171 98.7 -774 -1,030 0.0 0.0   Pre-tax profit (PTP)   2,354.1 445.9 128,771.7 -65,249.9 15,060.6 -5,907.8 0.0 0.0   Net earnings   2,311.1 344.5 128,738.7 -58,830.8 8,593.4 -5,899.3 0.0 0.0   Pre-tax profit without non-rec. items   2,354 446 128,772 -65,250 15,061 -5,908 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   4,700 4,936 133,325 69,494 73,087 65,188 41,663 41,663   Interest-bearing liabilities   20.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   5,392 5,163 133,707 69,537 73,404 65,622 41,663 41,663   Net Debt   -1,088 -664 -130,712 -53,491 -47,864 -38,674 -41,663 -41,663     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,155 467 571 98.7 -274 -180 0.0 0.0   Gross profit growth   0.0% -59.6% 22.3% -82.7% 0.0% 34.3% 0.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   5,392 5,163 133,707 69,537 73,404 65,622 41,663 41,663   Balance sheet change%   -31.4% -4.2% 2,489.5% -48.0% 5.6% -10.6% -36.5% 0.0%   Added value   384.7 216.8 170.7 98.7 -773.5 -1,029.7 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 -1.0 -2.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   33.3% 46.4% 29.9% 100.0% 282.8% 572.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   38.0% 8.7% 185.7% 8.6% 117.4% 2.2% 0.0% 0.0%   ROI %   40.8% 9.6% 186.5% 8.6% 52.3% -2.3% 0.0% 0.0%   ROE %   37.5% 7.1% 186.2% -58.0% 12.1% -8.5% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   87.2% 95.6% 99.7% 99.9% 99.6% 99.3% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -282.7% -306.1% -76,577.3% -54,217.9% 6,187.9% 3,755.8% 0.0% 0.0%   Gearing %   0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   1,649.5% 157.3% 0.0% 361,076,912.2% 108,461,804.9% 39,352,718.2% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   2.3 4.3 342.4 1,399.2 151.3 89.4 0.0 0.0   Current Ratio   2.3 4.3 342.4 1,399.2 151.3 89.4 0.0 0.0   Cash and cash equivalent   1,107.6 663.6 130,712.1 53,491.4 47,863.6 38,673.9 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   709.6 485.5 278.7 16,822.6 2,198.5 1,297.1 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   385 217 171 99 -774 -1,030 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   385 217 171 99 -774 -1,030 0 0   EBIT / employee   385 217 171 99 -774 -1,030 0 0   Net earnings / employee   2,311 344 128,739 -58,831 8,593 -5,899 0 0